Healthcare Valuation Multiples Are Compressing: What Buyers and Sellers Need to Know

The median enterprise value to EBITDA multiple across publicly traded healthcare services companies has declined to approximately 11.5x in 2026, down from 14.5x the prior year. That roughly 20% compression marks the end of a post-pandemic pricing cycle that saw healthcare transactions close at historically elevated levels. But the headline number obscures significant variation across subsectors, and for both buyers and sellers, the recalibration creates distinct strategic opportunities.

How the Post-Pandemic Premium Unwound

Healthcare M&A activity surged during 2021 through 2024, driven by a combination of factors: aging demographics, pent-up demand for healthcare services, aggressive PE deployment into the sector, and the accelerated adoption of technology-enabled care delivery models. Multiples expanded accordingly, with premium platforms in behavioral health, home health, and physician practice management routinely commanding 15x to 20x EBITDA or higher.

The unwinding began gradually in late 2024 and accelerated through 2025. Rising interest rates increased the cost of leverage, compressing the returns available to financial buyers at elevated multiples. Regulatory headwinds, including increased scrutiny of PE ownership of healthcare providers by the Federal Trade Commission, added uncertainty to the transaction environment. And the simple math of mean reversion took hold: valuations that had been stretched by competitive bidding and cheap debt began to normalize as both factors moderated.

By Q1 2026, the correction is visible in the public market data. The median EV/EBITDA multiple for healthcare services companies has settled around 11.5x, a level that is historically reasonable but represents a meaningful reset from the peaks of the prior cycle.

Where Compression Is Concentrated

The valuation reset is not hitting all healthcare subsectors equally. Understanding where multiples have compressed the most, and where they have held, is critical for both transaction planning and portfolio strategy.

The steepest declines have occurred in segments where the prior valuations were most dependent on growth assumptions and favorable financing conditions. Hospital systems and large physician practice management platforms, which attracted aggressive bidding from both strategic and financial buyers during the boom, have seen the most significant multiple contraction. Staffing and workforce solutions companies, which benefited from pandemic-era labor shortages, have also repriced as staffing dynamics normalize.

By contrast, several subsectors continue to command premium multiples. Ambulatory surgery centers, which benefit from the ongoing shift of procedures out of hospital settings, remain highly valued. Home-infusion services, driven by the expansion of specialty pharmacy and the preference for home-based care delivery, are trading at or near prior cycle levels. And behavioral health platforms, despite some cooling from peak levels, retain premium positioning due to persistent demand and limited supply of scaled providers.

What This Means for Sellers

For healthcare business owners considering a sale, the multiple compression does not necessarily mean that the window has closed. It means the market is more selective, and preparation matters more than it did when capital was abundant and buyers were competing aggressively for any healthcare asset.

The businesses that continue to attract premium interest share several characteristics: recurring or contractual revenue models, demonstrated margin stability, clinical quality metrics that support value-based care participation, and management teams with depth beyond the founder. Sellers who can present a clean quality of earnings report, a clear growth trajectory that does not depend on heroic assumptions, and a defensible market position will find that qualified buyers remain active.

The timing question is more nuanced than it might appear. While headline multiples have declined, the absolute number of PE firms and strategic buyers actively pursuing healthcare acquisitions remains robust. PwC's 2026 health services deal outlook confirms that both strategic and financial buyers continue to target the sector, with particular focus on defensible care delivery models and scalable technology. Waiting for a return to peak multiples may not be realistic, but transacting in a market where buyers are disciplined and terms are reasonable can produce better long-term outcomes than chasing the peak.

What This Means for Buyers

For acquirers, the valuation reset creates opportunities that were not available 18 months ago. Platform acquisitions that would have required 15x or higher can now be evaluated at more reasonable entry multiples, improving the return profile for both financial and strategic buyers.

The key for buyers is to distinguish between assets that have repriced because of sector-wide compression (creating genuine value opportunities) and those that have repriced because of company-specific deterioration. A quality of earnings analysis is essential in this environment. In a compressed-multiple market, the adjustments that a QoE reveals matter even more, because the margin for error on entry valuation is thinner.

Buy-and-build strategies remain particularly attractive. PE firms that acquire a healthcare platform at a reasonable entry multiple and execute disciplined add-on acquisitions can build scale and diversification while benefiting from the multiple arbitrage between smaller targets (trading at 6x to 8x) and scaled platforms (valued at 11x to 14x).